Michigan Gets Results with HCQ

BREAKING: ‘Trump Drug’ Hydroxychloroquine ‘Significantly’ Reduces Death Rate From COVID-19, Henry Ford Health Study Finds. H/T Jaime Jessop.  Excerpts in italics with my bolds

A Henry Ford Health System study shows the controversial anti-malaria drug hydroxychloroquine helps lower the death rate of COVID-19 patients, the Detroit-based health system said Thursday.

Officials with the Michigan health system said the study found the drug “significantly” decreased the death rate of patients involved in the analysis.

The study analyzed 2,541 patients hospitalized among the system’s six hospitals between March 10 and May 2 and found 13% of those treated with hydroxychloroquine died while 26% of those who did not receive the drug died.

Among all the patients in the study, there was an overall in-hospital mortality rate of 18%, and many who died had underlying conditions, the hospital system said. Globally, the mortality rate for hospitalized patients is between 10% and 30%, and 58% among those in the ICU or on a ventilator.

“As doctors and scientists, we look to the data for insight,” said Steven Kalkanis, CEO of the Henry Ford Medical Group. “And the data here is clear that there was a benefit to using the drug as a treatment for sick, hospitalized patients.”

A previous study by French doctors considered the efficacy of HCQ along with other widely available drugs during the several stages of Covid19.  The Michigan study shows benefits for people hospitalized in phases II and III.  The French study emphasized early use during phase I at onset of testing positive for SARS CV2.

See Pandemic Update: Virus Weaker, HCQ Stronger

HCQ Hit Job by Big Pharma Data Miners